News Release

FOR IMMEDIATE RELEASE

Theratechnologies achieves key milestones in 2005

- *Rapid progress with TH9507 Phase 3 trial in HIV-associated lipodystrophy – More than 200 patients enrolled*
- *Strategic decisions aimed at maximizing the value of the product portfolio*
- *Business and pharmaceutical experience added to the Board of Directors and management team*
- *$40 million in liquidities*

Montreal, February 8, 2006 – Theratechnologies (TSX: TH) announced today its financial results for the year ended November 30, 2005 and reviewed recent highlights.

"We hit all of our targets for the first Phase 3 clinical trial in HIV-associated lipodystrophy in 2005," said Yves Rosconi, President and Chief Executive Officer. "This project is the cornerstone of the strategy we are pursuing to build value for shareholders in the short term. From a financial perspective, we ended 2005 with $40 million in liquidities and we are able to finance our activities for nearly two years at the current burn rate," Mr. Rosconi added.

"For the longer term, our objective is to carefully select, develop and commercialize a series of products that have the same value-creating characteristics as TH9507 in HIV-associated lipodystrophy," Mr. Rosconi stated. "In this regard, THG213.29 in acute renal failure and TH9507 in cystic fibrosis and adult growth hormone deficiency are projects that will be advanced in 2006 and could become clinical programs in 2007.

"Coming back to 2006, we are focusing on completing patient recruitment by the end of the first quarter and the results of the first Phase 3 trial should be available in the fourth quarter. Assuming the results are positive, we will continue to move rapidly forward with the second Phase 3 trial in early 2007," Mr. Rosconi concluded.

Operating highlights:

Rapid progress with TH9507 Phase 3 trial in HIV-associated lipodystrophy
In March 2005, the FDA approved the phase 3 clinical trial protocol, including the use of an 8% reduction in visceral adipose tissue (VAT) as the primary endpoint. Health Canada subsequently approved the program as well. As planned, the first patient was treated in June 2005 and more than 200 patients have now been recruited. The Company expects to complete recruitment by the end of the first quarter and expects to announce the results of the first study in the final quarter of the year.

First diagnosed in 1998, HIV-associated lipodystrophy is a major metabolic complication that affects a growing number of HIV patients. There is no approved treatment for this disease. In 2005, Theratechnologies conducted research to evaluate the potential market for HIV-associated lipodystrophy. Based on public health statistics, scientific articles and market research, the Company estimates that the potential market for this indication in North America and Europe could be between US $425 million and US $850 million annually.

Theratechnologies Inc.
2310 Alfred-Nobel Blvd., Montréal, Quebec Canada H4S 2A4
Phone: (514) 336-7800 • Fax: (514) 336-7242 • www.theratech.com • thera@theratech.com

Strategic decisions aimed at maximizing the value of the product portfolio
In December 2005, Theratechnologies announced strategic decisions related to its product portfolio. THG213.29 in acute renal failure, TH9507 in cystic fibrosis and TH9507 in adult growth hormone deficiency are projects that the Company will consider. These three projects will be advanced in 2006 and could become clinical programs in 2007. At the same time, the type 2 diabetes and obesity programs have been designated candidates for out licensing.

Pharmaceutical experience added to the management team
In 2005, the Company named Chantal Desrochers, B. Ph., M.B.A. to the position of Vice President, Business Development and Commercialization, Koenraad Blot, M.D. to the position of Executive Director, Clinical Research, and finally Andrée Lefebvre, B.Sc. to the position of Executive Director, Compliance and Regulatory Affaires. All three appointees bring extensive pharmaceutical industry experience to their respective positions.

New members on the Board of Directors
The Board of Directors welcomed two new members in 2005 and a third in 2006. Robert Goyer, Ph.D, Emeritus Professor, Faculty of Pharmacy of Université de Montréal and Bernard Reculeau, who, until recently, was Senior Vice President Pharmaceutical Operations of Paris-based sanofi-aventis for the InterContinental Region, joined the Board in 2005. These two new members bring extensive pharmaceutical experience to Theratechnologies in development as well as in the commercialization of therapeutic products.

Effective today, the board welcomed Gérald A. Lacoste, former President of the Montreal Stock Exchange, who takes the place of André Delambre. Mr. Delambre, a member of the board since 1999, passed away in January after a courageous battle with amyotrophic lateral sclerosis (Lou Gehrig's disease).

$40 million in liquidities
At November 30, 2005, Theratechnologies had liquidities totaling $40 million, or almost two years of cash at the current burn rate. Among the highlights of the financial year, Theratechnologies completed an agreement with ALZA Corporation terminating three co-development projects and resulting in receipt of US $12 million. In June 2005, the Company sold its interest in Celmed BioSciences, a privately held oncology company, for an upfront payment of $2.8 million and future milestone payments of up to $5.6 million tied to the success of Celmed's lead products.

Scientific excellence
The Company earned recognition from its peers in 2005. The results of the Phase 2 clinical trial in HIV-associated lipodystrophy were published in the prestigious journal *AIDS.* In addition, eight poster presentations were made at important scientific conferences in the United States.

SUMMARY OF OPERATING RESULTS

Consolidation and investments
The consolidated financial statements include the accounts of Theratechnologies and its subsidiaries. On June 20, 2005, the Company closed the sale of its 37.3% investment in Celmed, a private company engaged in the field of oncology. Prior to that date, Theratechnologies' consolidated results included Celmed's results (see note 5 in the notes to the consolidated financial statements). For comparison purposes, results without Celmed are presented as additional information.

Revenues
Theratechnologies' consolidated revenues for the year ended November 30, 2005 were exceptionally high at $16,461,000, compared to $2,649,000 ($2,093,000 without Celmed) in 2004. The increase is essentially due to the payment of $14,640,000 (US$12,000,000) received in connection with the Company's December 2004 agreement with ALZA to terminate three co-development projects using ALZA's Macroflux® transdermal technology. The decrease in interest revenues is due to a reduction of the liquidities (cash and bonds) as well as the maturity of certain high-yield investments.

R&D activities
Consolidated research and development (R&D) expenditures, before tax credits, totalled $14,987,000 for the year ended November 30, 2005, compared to $18,439,000 ($14,380,000 without Celmed) in 2004. The R&D spending, for the year ended November 30, 2005, was comparable to the same period in 2004. TH9507 accounts for most of the expenditures in 2005, however, a relatively large portion of expenditures in 2004 were related to ThPTH and TH0318, two programs that will not be pursued by the Company.

Tax credits
Tax credits amounted to $1,217,000 for the year ended November 30, 2005, compared to $1,472,000 in 2004. Tax credits represent reimbursable tax credits obtained from the Québec Government. The decrease is due to a reduction in admissible expenses in 2005.

Other expenses
For the year ended November 30, 2005, general and administrative expenses, selling and market development expenses, patents and amortization of other assets ("SG&A") were $7,702,000, compared to $8,552,000 ($6,535,000 without Celmed) in 2004. Several elements account for this increase, the first of which are measures, launched at the end of 2004, to put in place the infrastructures required to support the late-stage development of TH9507 and its future commercialization. Another element is a $463,000 write off of certain patent costs and deferred development expenses, following management's reassessment of its strategy regarding non-core products and the related patent portfolio.

Proportionate share in loss of companies under significant influence
The proportionate share in loss of Celmed and Andromed was $6,673,000, compared to $7,867,000 in 2004. In 2005, Celmed's losses were accounted for until the Company sold its interest in Celmed (June 2005). Prior to the date of sale, Celmed recorded a non-cash write down, net of related income taxes, of $9,685,000, yielding a proportionate share of $4,069,000 for Theratechnologies, in connection with the acquisition of NewBiotics' intellectual property in 2004.

In 2004, Celmed's losses were accounted for by the equity method after July 2, 2004 (See note 5 in the consolidated financial statements). At November 30, 2004, Celmed reviewed the book value of the intellectual property acquired with the acquisition of NewBiotics, as per the Handbook of the Canadian Institute of Chartered Accountants. Pursuant to this analysis, Celmed recorded a write-down of these assets and a related decrease in future income taxes, resulting in a non-cash loss of $11,117,000, of which Theratechnologies' proportionate share was $4,670,000.

Gains on investments in companies and gains on dilution
On June 20, 2005, the Company completed the sale of its 37,3% interest in Celmed for total proceeds of up to $8,400,000. The proceeds include an upfront payment of $2,811,000, as well as milestone payments tied to the success of Celmed's more advanced products totalling $5,589,000. The milestone payments will be recorded once the related milestones are reached. Consequently, a non-cash write down of $2,659,000 was recorded in 2005.

During the year ended November 30, 2004, the Company realized gains on investments in companies and gains on dilution of $5,808,000. These gains are detailed in note 5 of the consolidated financial statements.

Net results
Reflecting the variations in revenues and expenses described above, the Company recorded for the year ended November 30, 2005, an operating loss $5,011,000 (before proportionate share in loss of companies under significant influence, losses on investments in companies and gains on dilution, non-controlling interest and discontinued operations), compared to a loss of $22,870,000 in 2004. The net loss amounted to $14,343,000 in 2005, compared to $22,816,000 in 2004.

Quarterly financial information

The selected financial information provided below is derived from the Company's unaudited quarterly financial statements for each of the last eight quarters. This information includes Celmed's results until July 2, 2004. (See note 5 in the notes to the consolidated financial statements).

(In thousands of Canadian dollars,
except per share amounts)

	2005				2004			
	Q4	**Q3**	**Q2**	**Q1**	Q4	Q3	Q2	Q1
Revenues	**$ 319**	**$ 409**	**$ 631**	**$ 15,102**	$ 503	$ 585	$ 782	$ 779
Operating earnings (loss) (1)	**$ (5,580)**	**$ (5,065)**	**$ (4,784)**	**$ 10,418**	$ (4,655)	$ (4,289)	$ (6,832)	$ (7,094)
Earnings (loss) from continuing operations(2)	**$ (5,651)**	**$ (5,218)**	**$ (12,745)**	**$ 9,271**	$ (10,873)	$ (4,137)	$ (6,139)	$ (1,731)
Net earnings (loss)	**$ (5,651)**	**$ (5,218)**	**$ (12,745)**	**$ 9,271**	$ (10,873)	$ (4,150)	$ (5,910)	$ (1,883)
Basic and diluted earnings (loss) per share:								
Continuing activities (2)	**$ (0.16)**	**$ (0.15)**	**$ (0.36)**	**$ 0.26**	$ (0.31)	$ (0.12)	$ (0.17)	$ (0.06)
Net earnings (loss)	**$ (0.16)**	**$ (0.15)**	**$ (0.36)**	**$ 0.26**	$ (0.31)	$ (0.12)	$ (0.17)	$ (0.06)

(1) Before restructuring costs, proportionate share in loss of companies under significant influence, gains on investments in companies and gains on dilution, discontinued operations and non-controlling interest
(2) Net of non-controlling interest

In the first quarter of 2005, the revenue increase is essentially due to the payment of $14,640,000 (US$12,000,000) received in connection with the Company's December 2004 agreement with ALZA to terminate three co-development projects using ALZA's Macroflux® transdermal technology.

In the second quarter of 2005, the increase in loss results from a non-cash loss, net of related income tax, of $9,685,000 recorded by Celmed at May 31, 2005, in relation to the intellectual property acquired from NewBiotics in 2004, representing a proportionate share of $4,069,000 for Theratechnologies. The Company also recognized a non-cash loss of $2,659,000 in the second quarter related to the sale of its 37.3% interest in Celmed.

Fourth quarter

Theratechnologies' consolidated revenues for the three-month period ended November 30, 2005 amounted to $319,000, compared to $503,000 for the same period in 2004. The decrease in revenues for 2005 is attributed to a decrease in interest revenues resulting from reduced liquidities (cash and bonds) as well as the maturity of certain high-yield investments.

Consolidated research and development (R&D) expenditures, before tax credits, for the fourth quarter of 2005, totaled $4,666,000, compared to $3,563,000 in 2004. The increase in R&D expenditures for the quarter was largely due to expenditures related to the TH9507 Phase 3 study in HIV-associated lipodystrophy, for which the first patient was treated in June 2005.

General and administrative expenses, selling and market development expenses, patents and amortization of other assets for the fourth quarter of 2005 were comparable to those of 2004.

For the fourth quarter of 2005, the proportionate share in losses of companies under significant influence was estimated at $71,000, compared to $6,237,000 in 2004. The decrease results from ceasing to account for Celmed's losses during the third quarter of 2005, following the sale of the Company's interest in Celmed in June 2005. In 2004, Celmed reviewed the book value of the intellectual property acquired with the acquisition of NewBiotics, as per the Handbook of the Canadian Institute of Chartered Accountants. Pursuant to this analysis, Celmed recorded a write-down of these assets and a related decrease in future income taxes, resulting in a non-recurring loss of $11,117,000, of which Theratechnologies' proportionate share was $4,670,000.

Consequently, the Company recorded, for the fourth quarter ended November 30, 2005, an operating loss of $5,580,000, before proportionate share in loss of a company under significant influence, gains on investments in companies and gains on dilution, compared to $4,655,000 in 2004. The net loss for the fourth quarter of 2005 was $5,651,000, compared to $10,873,000 in 2004.

For the three-month period ended November 30, 2005, the burn rate relating to operating activities, excluding changes in operating assets and liabilities, was $5,196,000, compared to $4,286,000 in 2004, reflecting higher R&D expenses as described previously.

Liquidity and capital resources

Theratechnologies maintained an adequate cash position in 2005. At November 30, 2005, liquidities (cash and bonds) amounted to $39,026,000 and tax credits receivable amounted to $978,000, for a total amount of $40,004,000.

For the year ended November 30, 2005, the burn rate, represented by cash flows from operating activities and excluding changes in operating assets and liabilities, was $3,141,000, reflecting the $14,640,000 revenue from the ALZA Corporation transaction, compared to $20,776,000 ($15,941,000 without Celmed) in 2004.

In 2005, Theratechnologies issued 39,436 common shares to employees for a cash consideration of $65,000. In 2004, Theratechnologies issued, as part of an offering, 4,542,500 common shares for a cash consideration of $15,672,000, including the over-allotment option. During the year ended November 30, 2004, the Company also issued 52,418 common shares to employees for cash consideration of $131,000.

As stated previously, the Company received a cash consideration of $2,561,000 ($2,811,000 before related fees) following the sale of its interest in Celmed.

Outstanding share data

At February 8, 2006, the number of shares issued and outstanding was 35,552,985 common shares, while outstanding options granted under the stock option plan were 2,811,500. In addition, 1,080,000 warrants were outstanding.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets where it can retain full or partial commercial rights for its products. Its most advanced program is TH9507, now in Phase 3 clinical trials for a serious metabolic syndrome known as HIV-associated lipodystrophy. The Company also has other promising projects at earlier stages of development.

Additional information about Theratechnologies

Further information relating to Theratechnologies is available on the Company's website at http://www.theratech.com/. The Company is listed on the Toronto Stock Exchange under the symbol TH. Additional information, including the Company's Annual Information Form, is available on SEDAR at www.sedar.com.

Forward-looking statements

This press release contains forward-looking statements regarding the future orientations of the Company and its financial position, the creation of value for the shareholders, and the clinical development of TH9507 and THG213.29 and their future commercialization in the indications described above. Such statements inherently involve numerous risks and uncertainties, including the availability of funds and resources, the success and timely completion of clinical trials and the granting of the necessary authorizations. Actual future results may differ materially from the anticipated results. Investors are cautioned against placing undue importance on forward-looking information contained herein and should consult the Company's 2004 Annual Report, which contains a more exhaustive analysis of risks and uncertainties connected to the businesses of the Company.

To obtain additional information, contact:

Yves Rosconi
President and Chief Executive Officer
Phone: 514-336-4804, ext. 203
yrosconi@theratech.com

Luc Tanguay
Senior Executive Vice President and Chief Financial Officer
Phone: 514-336-4804, ext. 204
ltanguay@theratech.com

Marie-Noël Colussi
Vice President, Finance
Phone: 514-336-4804, ext. 237
mncolussi@theratech.com

THERATECHNOLOGIES INC.
CONSOLIDATED BALANCE SHEET
(in thousands of dollars)

	November 30 2005 (audited)	November 30 2004 (audited)
Assets		
Current assets:		
Cash	$ 1,087	$ 436
Bonds	12,515	17,513
Accounts receivable	258	395
Tax credits receivable	978	754
Research supplies	1,929	1,542
Prepaid expenses	425	202
	17,192	20,842
Bonds	25,424	24,105
Investments in public companies (market value : $1,424 in 2005; $3,026 in 2004)	836	1,362
Investment in a private company (note 5)	-	11,367
Property and equipment	2,072	2,234
Other assets (note 2)	8,121	8,040
	$ 53,645	$ 67,950
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	$ 4,639	$ 4,996
Shareholders' equity:		
Capital stock (note 3)	155,659	155,594
Contributed surplus	2,587	2,257
Deficit	(109,240)	(94,897)
	49,006	62,954
	$ 53,645	$ 67,950

See accompanying notes to unaudited consolidated financial statements.

THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENT OF EARNINGS
PERIODS ENDED NOVEMBER 30
(in thousands of dollars, except per share amounts)

	Fourth quarter		Year	
	2005	2004	**2005**	2004
	(unaudited)	(unaudited)	**(audited)**	(audited)
Revenues:				
Royalties, technologies and other (note 4)	**$ 6**	$ 55	**$ 14,856**	$ 269
Interest	**313**	448	**1,605**	2,380
	319	503	**16,461**	2,649
Operating costs and expenses:				
Research and development	**4,666**	3,563	**14,987**	18,439
Tax credits	**(543)**	(313)	**(1,217)**	(1,472)
	4,123	3,250	**13,770**	16,967
General and administrative	**1,378**	1,305	**5,452**	6,640
Selling and market development	**185**	297	**980**	1,016
Patents and amortization of other assets (note 2)	**213**	306	**1,270**	896
	5,899	5,158	**21,472**	25,519
Operating loss before undernoted items	**(5,580)**	(4,655)	**(5,011)**	(22,870)
Proportionate share in loss of companies under significant influence	**(71)**	(6,237)	**(6,673)**	(7,867)
(Loss) gains on investments in companies and gains on dilution (note 5)	**-**	19	**(2,659)**	5,808
Loss from continuing operations before non-controlling interest	**(5,651)**	(10,873)	**(14,343)**	(24,929)
Gain from discontinued operations (note 6)	**-**	-	**-**	109
Non-controlling interest	**-**	-	**-**	2,004
Net loss	**$ (5,651)**	$ (10,873)	**$ (14,343)**	$ (22,816)
Basic and diluted loss per share (note 3 b):				
Continuing operations non-controlling interest deducted	**$ (0.16)**	$ (0.31)	**$ (0.40)**	$ (0.66)
Net loss	**(0.16)**	(0.31)	**(0.40)**	(0.66)
Weighted average number of common shares outstanding	**35,550,283**	35,488,254	**35,534,466**	34,476,299

See accompanying notes to consolidated financial statements.

THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
PERIODS ENDED NOVEMBER 30
(in thousands of dollars)

	Fourth quarter		Year	
	2005	2004	**2005**	2004
	(unaudited)	(unaudited)	**(audited)**	(audited)
Cash flows from operating activities:				
Net loss	**$ (5,651)**	$ (10,873)	**$ (14,343)**	$ (22,816)
Adjustments for:				
Depreciation of property and equipment	**163**	156	**594**	779
Depreciation of other assets	**144**	130	**946**	523
Stock-based compensation	**77**	83	**330**	792
Proportionate share in loss of companies under significant influence	**71**	6,237	**6,673**	7,867
Loss (gains) on investments in companies and gains on dilution	**-**	(19)	**2,659**	(5,808)
Gain from discontinued operations	**-**	-	**-**	(109)
Non-controlling interest	**-**	-	**-**	(2,004)
	(5,196)	(4,286)	**(3,141)**	(20,776)
Change in operating assets and liabilities:				
Interest receivable on bonds	**91**	98	**501**	210
Accounts receivable	**131**	(163)	**137**	(20)
Tax credits receivable	**454**	613	**(224)**	(541)
Research supplies	**251**	364	**(1,245)**	304
Prepaid expenses	**273**	176	**(223)**	(173)
Accounts payable and accrued liabilities	**1,015**	1,530	**(142)**	(556)
	2,215	2,618	**(1,196)**	(776)
Cash used in discontinued operations	**-**	(25)	**-**	(449)
	(2,981)	(1,693)	**(4,337)**	(22,001)
Cash flows from financing activities:				
Share issue	**5**	82	**65**	15,803
Share issue costs	**-**	(2)	**-**	(1,159)
	5	80	**65**	14,644
Cash flows from investing activities:				
Addition to property and equipment	**(122)**	(194)	**(581)**	(646)
Disposal of property and equipment	**-**	-	**-**	122
Addition to other assets	**(9)**	(26)	**(235)**	(728)
Acquisition of bonds	**(3,375)**	(3,237)	**(14,306)**	(29,339)
Disposal of bonds	**2,800**	5,401	**17,484**	37,559
Disposal of shares in a private company, net amount	**-**	-	**2,561**	-
Acquisition of shares in a public companies	**-**	(349)	**-**	(349)
Disposal of shares in public companies	**-**	-	**-**	2,481
Net investments related to discontinued operations	**-**	-	**-**	10
	(706)	1,595	**4,923**	9,110
Cash related to Celmed	**-**	-	**-**	(1,370)
Net change in cash	**(3,682)**	(18)	**651**	383
Cash, beginning of period	**4,769**	454	**436**	53
Cash, end of period	**$ 1,087**	$ 436	**$ 1,087**	$ 436

See accompanying notes to consolidated financial statements.
See note 8 a) for supplemental cash flow information.

THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF DEFICIT
YEARS ENDED NOVEMBER 30, 2005 AND 2004
(in thousands of dollars)

		2005		2004
		(audited)		(audited)
Deficit, beginning of year	**$**	**(94,897)**	$	(70,922)
Net loss		**(14,343)**		(22,816)
Share issue costs		**-**		(1,159)
Deficit, end of period	**$**	**(109,240)**	$	(94,897)

See accompanying notes to consolidated financial statements.

THERATECHNOLOGIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED NOVEMBER 30, 2005 AND 2004
(in thousands of dollars, except per share amounts) (unaudited)

1. Basis of presentation

The financial statements included in this report are unaudited and reflect normal and recurring adjustments, which are in the opinion of the Company, considered necessary for a fair presentation. These financial statements have been prepared in conformity with Canadian generally accepted accounting principles. The same accounting policies as described in the Company's latest annual report have been used. However, these financial statements do not include all disclosures required under generally accepted accounting principles and accordingly should be read in connection with the financial statements and the notes thereto included in the Company's latest annual report. These interim financial statements have not been reviewed by auditors.

2. Other assets

During the first half of 2005, management reassessed its strategy regarding non-core products and the related patent portfolio. As a result, the Company recorded a write off of $463 for certain patent costs and deferred development expenses.

3. Capital stock

		2005		2004
Authorized in unlimited number and without par value:				
Common shares				
Preferred shares issuable in one or more series				
Issued:				
35,552,985 common shares (35,513,549 in 2004)	**$**	**155,659**	$	155,594

During the year of 2005, the Company issued 39,436 shares for cash consideration of $65.

3. Capital stock (cont'd)

a) Stock-based compensation and other stock-based payments

The weighted-average fair value of the 535,000 options granted during the year ended November 30, 2005 is $0.84 per option. The fair value of the options granted during 2005 was estimated at the date of grant using the Black-Scholes option pricing model with the following assumptions: risk-free interest rate of 3.71%, expected dividend yield of nil, expected volatility of 51% and an average expected option life of 6 years.

b) Diluted loss per share

Diluted loss per share was not presented as the effect of options and warrants would have been anti-dilutive. Furthermore, the exercise of options and warrants would not have been considered in such computation since their exercise prices were higher than the average market price during the reporting periods of 2004 and 2005.

4. Royalties, technologies and other

In December 2004, the Company completed an agreement to terminate three co-development projects using ALZA Corporation's Macroflux® transdermal technology. The Company retains the rights to develop its molecules with all other means of delivery and ALZA retains the commercialization rights to Macroflux® with other molecules. In this regard, the Company received a payment of $14,640 (US $12,000).

5. (Loss) gains on investments in companies and gains on dilution

2005:
On June 20, 2005, the Company completed the sale of its 37.3% interest in Celmed BioSciences for total proceeds of up to $8,400. The acquirer is a group of minority shareholders of Celmed. The proceeds include an upfront payment of $2,811, as well as milestone payments tied to the success of Celmed's more advanced products totalling $5,589. The milestone payments will be recorded once the related milestones are reached. The Company recorded a reduction in value of $2,659 in relation to the sale of its shares in Celmed on June 20, 2005.

2004:
During the year ended November 30, 2004, the Company realized gains on investments in companies of $2,018 resulting from the disposal of shares in public companies.

In January and February 2004, Celmed's institutional investors exercised adjustment clauses in relation to their investment, thus reducing the Company's interest in Celmed from 61.6% to 56.1%. In February 2004, Celmed proceeded with the redemption for a nominal amount of shares of certain shareholders because the milestones related to these shares were not achieved. In April 2004, Celmed proceeded with the redemption of shares of a non-controlling shareholder in connection with the sale of a US subsidiary. These redemptions resulted in an increase of the Company's interest in Celmed to 59.7%. As a result of these transactions, the deferred gain of $3,762 at November 30, 2003 was attributed to non-controlling interests, and the adjustment to their interest resulted in a gain of $2,725, which was included in the statement of earnings for 2004.

As a result of the issuance of shares by Celmed to acquire NewBiotics Inc. on July 2, 2004, Theratechnologies' interest in Celmed was reduced from 59.7% to 42%. An adjustment clause in connection with the interest of founding investors later reduced the Company's interest to 37.3%. The Company recognized a gain of $1,046 in 2004.

The Company also realized a gain of $19 in 2004 resulting from issuance of shares to third parties by Andromed.

(in thousands of dollars, except per share amounts) (unaudited)

6. Discontinued operations

During the first quarter of 2004, Celmed studied the relevance of pursuing its activities in the treatment of Parkinson's disease. In this context, Celmed discontinued its development activities for this program. In April 2004, Celmed disposed of the shares of its US subsidiary in the field of neurology. Consequently, operating results for these activities have been reclassified under item "Discontinued operations". The results are shown below:

	Fourth quarter **2005**	Fourth quarter 2004	Year **2005**	Year 2004
Costs and expenses:				
General and administrative	**$ -**	$ -	**$ -**	$ (20)
Research and development	**-**	-	**-**	322
Patents and amortization of other assets	**-**	-	**-**	21
Gain on disposal of subsidiary	**-**	-	**-**	(432)
Gain from discontinued operations	**$ -**	$ -	**$ -**	$ 109
Gain from discontinued operations attributable to parent company	**$ -**	$ -	**$ -**	$ 64
Non-controlling interest before discontinued activities	**$ -**	$ -	**$ -**	$ 2,049
Loss from continuing operations, net of non-controlling interest	**$ (5,651)**	$ (10,873)	**$ (14,343)**	$ (22,880)

7. Segmented information

	Therapeutic peptides	Cell therapy	Other segments	Intersegment adjustments and eliminations	Total
Fourth quarter ended November 30, 2005					
Revenues from external customers	**$ 6**	**$ -**	**$ -**	**$ -**	**$ 6**
Revenues from companies under significant influence	**-**	**-**	**-**	**-**	**-**
Loss from continuing operations	**(5,580)**	**-**	**(71)**	**-**	**(5,651)**
Net loss	**(5,580)**	**-**	**(71)**	**-**	**(5,651)**
Total assets	**52,809**	**-**	**836**	**-**	**53,645**
Twelve months ended November 30, 2005					
Revenues from external customers	**$ 14,836**	**$ -**	**$ -**	**$ -**	**$ 14,836**
Revenues from companies under significant influence	**20**	**-**	**-**	**-**	**20**
Loss from continuing operations	**(5,011)**	**(6,147)**	**(526)**	**(2,659)**	**(14,343)**
Net loss	**(5,011)**	**(6,147)**	**(526)**	**(2,659)**	**(14,343)**
Total assets	**52,809**	**-**	**836**	**-**	**53,645**

THERATECHNOLOGIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
YEARS ENDED NOVEMBER 30, 2005 AND 2004
(in thousands of dollars, except per share amounts) (unaudited)

7. Segmented information (cont'd)

	Therapeutic peptides	Cell therapy (1)	Other segments	Intersegment adjustments and eliminations	Total
Fourth quarter ended November 30, 2004					
Revenues from external customers	**$ 34**	**$ -**	**$ -**	**$ -**	**$ 34**
Intersegment revenues	**21**	**-**	**-**	**-**	**21**
Loss from continuing operations	**(4,656)**	**(6,024)**	**(212)**	**19**	**(10,873)**
Net loss	**(4,656)**	**(6,024)**	**(212)**	**19**	**(10,873)**
Total assets	**55,238**	**11,367**	**1,408**	**(63)**	**67,950**
Twelve months ended November 30, 2004					
Revenues from external customers	**$ 242**	**$ -**	**$ -**	**$ -**	**$ 242**
Intersegment revenues	**85**	**-**	**-**	**(58)**	**27**
Loss from continuing operations	**(17,624)**	**(11,933)**	**(939)**	**7,616**	**(22,880)**
Net loss	**(17,624)**	**(11,869)**	**(939)**	**7,616**	**(22,816)**
Total assets	**55,238**	**11,367**	**1,408**	**(63)**	**67,950**

(1) The net loss for this sector was reduced by the non-controlling interest

8. Supplemental information

a) The following transactions were concluded by the Company and did not impact cash flow.

	2005	2004
Addition to property and equipment et other assets financed by accounts payable and accrued liabilities	**$ 163**	$ 378

b) General and administrative expenses include a loss on exchange of $36 for the fourth quarter of 2005 (gain of $27 in 2004) and a loss of $112 for the year ended November 30, 2005 (gain of $122 in 2004).

# # #